Blog

Petrelintide Just Dropped Its Type 2 Diabetes Numbers - And The Tolerability Story Gets Better

Zealand and Roche's amylin analog hit 9.2% weight loss in type 2 diabetes and slowed heart rate instead of raising it. Here is the topline and what it means.

The amylin race just got a fresh data point, and it came from the harder population. Overnight, Zealand Pharma announced topline results from ZUPREME-2, the phase 2 trial of petrelintide in people with overweight or obesity and type 2 diabetes. The read: 7.4% to 9.2% weight loss at 28 weeks depending on dose, versus 2% on placebo.

If that sounds modest next to the incretin headlines, you are missing the part the community is actually buzzing about: petrelintide is doing its work without the classic GLP-1 side-effect load, and it appears to be lowering heart rate rather than raising it.

What the Research Says

From Reuters’ coverage of the October 7 announcement and Zealand’s topline release:

  • The 220-patient trial met its primary endpoint, with once-weekly petrelintide producing 7.4% to 9.2% body weight loss at 28 weeks, versus 2% with placebo
  • HbA1c fell by up to 0.65 percentage points on petrelintide, while it rose 0.23 points in the placebo group - a meaningful swing in a diabetes population
  • Only 1.9% of participants discontinued due to gastrointestinal side effects, versus 1.7% on placebo. Read that again: tolerability essentially indistinguishable from placebo
  • Most GI events were mild and confined to the dose-escalation window

This lands one week after the full peer-reviewed dataset from ZUPREME-1, the phase 2 in people without diabetes, published in The Lancet Diabetes & Endocrinology on September 29 and presented at EASD Milan. That trial showed up to 10.7% weight loss at 42 weeks versus 1.7% on placebo (Lancet Diabetes & Endocrinology, NCT06662539), with nausea in 20% of participants but vomiting in only 3% - and serious adverse events at 3% versus 4% on placebo.

The cardiometabolic secondary data from ZUPREME-1 is worth a closer look, per Zealand’s September 30 release:

  • Waist circumference down 10.8 cm versus 4.3 cm on placebo
  • hsCRP down up to 41% versus 6% on placebo - a big inflammation signal
  • Triglycerides down 21% versus 9%
  • And the outlier: mean pulse rate fell up to 2.9 bpm versus a rise of 0.3 bpm on placebo

That last number is the interesting one. Nearly every incretin raises heart rate by 1-7 bpm across trials. An amylin analog that nudges pulse the other way suggests a genuinely different mechanism doing the appetite work.

Why Amylin Is the Hedge Against the GLP-1 Playbook

Amylin is the peptide hormone co-secreted with insulin after meals. It signals satiety through its own receptor pathway, partly by restoring sensitivity to leptin, the body’s original fullness hormone. Because it is a separate pathway from GLP-1 and GIP, the amylin story has always been: lower side-effect load, smoother weight loss, and a natural stacking partner.

Novo has been betting the same way with cagrilintide, both standalone and inside CagriSema, and with zenagamtide, its single-molecule GLP-1/amylin build. Zealand and Roche are running the purer experiment: petrelintide alone, then petrelintide stacked on enicepatide, Roche’s GLP-1/GIP dual agonist, in a combination phase 2 planned for later this year.

The trade-off is honest too. Ten percent weight loss is well short of what the triple agonists are posting - we covered retatrutide’s 25% readout from TRIUMPH-1. Zealand’s own lead investigator, Dr Timothy Garvey of the University of Alabama at Birmingham, told HCPLive that the 10-15% class is “sufficient to treat a large number of patients who have obesity”. Whether the market pays incretin prices for incretin-minus efficacy is the commercial question the phase 3 program will answer.

The Australian Angle

Petrelintide is not approved anywhere and is not available by prescription in Australia. Roche bought into the program through a collaboration worth up to $5.3 billion, and the companies have started the phase 3 ZUPREME registrational program - three trials, roughly 7,000 participants, covering people without diabetes, with type 2 diabetes, and with established cardiovascular disease. The cardiovascular outcomes arm (ZUPREME-5) runs its primary endpoint at week 64 and can run three years, which signals the sponsors want the outcome data PBS and FDA reviewers increasingly demand.

Realistically: no Australian regulatory pathway before 2028 at the earliest, and that assumes clean phase 3 data. Anything sold as “petrelintide” today is not petrelintide. The TGA has been flagging unapproved peptide products all year - our TGA peptide seizure coverage has the background.

Want to talk amylin versus incretins with people who read the same papers? Join our Telegram community.

Sources

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.